GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Price-to-Free-Cash-Flow

Intra-Cellular Therapies (Intra-Cellular Therapies) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Intra-Cellular Therapies Price-to-Free-Cash-Flow?

As of today (2024-04-25), Intra-Cellular Therapies's share price is $71.70. Intra-Cellular Therapies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.30. Hence, Intra-Cellular Therapies's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Intra-Cellular Therapies's Price-to-Free-Cash-Flow or its related term are showing as below:

ITCI's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 21.73
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Intra-Cellular Therapies's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.02. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.30.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 26.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 5.40% per year.

During the past 12 years, Intra-Cellular Therapies's highest 3-Year average Free Cash Flow per Share Growth Rate was 26.50% per year. The lowest was -49.60% per year. And the median was -10.60% per year.


Intra-Cellular Therapies Price-to-Free-Cash-Flow Historical Data

The historical data trend for Intra-Cellular Therapies's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Price-to-Free-Cash-Flow Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intra-Cellular Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intra-Cellular Therapies's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Price-to-Free-Cash-Flow falls into.



Intra-Cellular Therapies Price-to-Free-Cash-Flow Calculation

Intra-Cellular Therapies's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=71.70/-1.299
=N/A

Intra-Cellular Therapies's Share Price of today is $71.70.
Intra-Cellular Therapies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Intra-Cellular Therapies  (NAS:ITCI) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Intra-Cellular Therapies Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Executives
Sharon Mates director, officer: Chairman, President & CEO C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead officer: SVP and General Counsel C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam officer: Chief Medical Officer C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann officer: EVP, Chief Commercial Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline officer: VP of Finance, CFO & Secretary C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas director C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi director, 10 percent owner P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin officer: EVP and Chief Medical Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover officer: VP, Clinical Development C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis officer: SVP, Chief Scientific Officer 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi 10 percent owner 1311 ORLEANS DRIVE, SUNNYVALE CA 94089